A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)

Trial Profile

A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 27 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.
    • 25 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018 as per ClinicalTrials.gov record.
    • 25 Mar 2016 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top